Oral vasoactive medication in intermittent claudication: utile or futile?
OBJECTIVE
To evaluate the role of orally administered vasoactive medication in the management of intermittent claudication.


METHODS
We limited our study to the products on the market in Belgium: cinnarizine, cyclandelate, isoxsuprine, naftidrofuryl, pentoxifylline, xanthinol nicotinate and buflomedil.


METHODS
We conducted a systematic literature search involving Medline, International Pharmaceutical Abstracts, the Cochrane Library, direct contact with marketing companies and key authors, snowballing and Science Citation Index search. We looked for randomised placebo-controlled trials (RCTs) in patients with Fontaine stage II, in which pain-free and/or maximal walking distance were measured using a standardised exercise test. For isoxsuprine and xanthinol nicotinate, no trials conforming to these criteria were found. Thirty-six trials on cinnarizine, cyclandelate, buflomedil, naftidrofuryl and pentoxifylline met our inclusion criteria.


METHODS
After quality assessment, 26 trials were excluded, mainly because of short trial duration (less than 12 weeks), small sample size (less than 30 patients) and/or failure to report details on variability (standard deviation or confidence limits). For cinnarizine and cyclandelate, none of the three selected RCTs was included.


METHODS
For buflomedil, of six published RCTs, two were included after quality assessment, each showing a marginally positive effect of buflomedil versus placebo. For naftidrofuryl, nine RCTs were selected; six were included of which five showed a significant positive result. The likelihood of publication bias and the heterogeneity of the results within and between trials precluded a meta-analysis. For pentoxifylline, of the 18 selected RCTs, only two could be included, both with inconclusive results.


CONCLUSIONS
A national consensus conference, based on this review, concluded that health resources should be allocated to prevention and rehabilitation of intermittent claudication rather than to reimbursement of these products with doubtful efficacy.
De Backer
T L
TL
Heymans Institute of Pharmacology, Ghent University Medical School, Belgium.
Vander Stichele
R H
RH
Warie
H H
HH
Bogaert
M G
MG
D000284:Administration, Oral; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy*; D009257:Nafronyl / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D011759:Pyrrolidines; D009257:Nafronyl; D010431:Pentoxifylline; C010651:buflomedil